Biocytogen inks antibody deal with BeOne, expanding strategic ties
China-based biotech Biocytogen (HKEX: 02315) has signed a global licensing agreement with oncology-focused BeOne Medicines (SHA: 688235), handing over rights to multiple fully human antibodies discovered through its proprietary RenMice platform.
The deal builds on an earlier arrangement under which BeOne had already licensed access to Biocytogen’s antibody discovery technology. Biocytogen will receive an undisclosed upfront payment as part of the new agreement and is in line for additional development and commercial milestone payments, as well as tiered royalties on future sales.
BeOne will now gain broader access to antibody assets sourced from the RenMice system, which supports the development of fully human monoclonal and bispecific antibodies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze